In 2016, Daniele et al. optimized 2-phenylindolylglyoxylyldipeptide,a lead dual inhibitor of MDM-2 and TSPO (137, MDM/p53interaction IC50 = 11.65 nM, TSPO Ki = 438 nM), to treat gliomas.86 To optimize the structural features, six compounds were synthesizedand investigated as MDM2/p53 complex disruptors in U-87MG cells. The gene discussed is TSPO; the disease is central nervous system cancer.